OSLO, Norway, May 6, 2026
Zelluna ASA announced the activation of the first clinical site for its ZIMA-101 Phase 1 clinical trial, marking a major operational milestone as the company transitions from clinical preparation into active trial execution for its lead investigational cell therapy candidate, ZI-MA4-1. The first activated site is The Christie NHS Foundation Trust in the United Kingdom, where Professor Fiona Thistlethwaite will serve as Chief Investigator for the study. The activation officially initiates clinical operations for Zelluna’s first-in-human study evaluating its proprietary T Cell Receptor-based Natural Killer (TCR-NK) cell therapy platform for the treatment of solid cancers. The company stated that additional clinical site activations, including The Royal Marsden, are expected shortly as patient screening activities begin ahead of anticipated first patient dosing.
ZIMA-101 Advances Zelluna’s First-in-Human TCR-NK Cell Therapy Program
The ZIMA-101 study is a Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead allogeneic “off-the-shelf” TCR-NK cell therapy designed to target MAGE-A4, a cancer-testis antigen commonly expressed across multiple solid tumor types. According to the company, ZI-MA4-1 represents the world’s first MAGE-A4-targeting TCR-NK therapy to enter clinical development. The investigational therapy combines the tumor-targeting specificity of engineered T Cell Receptors with the innate anti-cancer killing ability of Natural Killer cells, creating a next-generation immunotherapy platform intended to address longstanding limitations associated with current solid tumor cell therapies.
Unlike traditional autologous CAR-T therapies that require individualized patient cell manufacturing, Zelluna’s allogeneic approach is designed to function as a scalable, ready-to-use treatment platform. The company believes this strategy could potentially reduce manufacturing complexity, improve accessibility, and shorten treatment timelines for patients with aggressive solid tumors. The activation of the first clinical site follows earlier approval of Zelluna’s Clinical Trial Application (CTA) by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC), which the company announced in February 2026.
Solid Tumor Immunotherapy Remains a Major Industry Challenge
Advertisement
While cell therapies have transformed treatment options for several blood cancers, achieving similar success in solid tumors has proven significantly more difficult due to tumor microenvironment barriers, immune suppression, and limited tumor targeting specificity. Zelluna’s TCR-NK platform is specifically designed to overcome some of these challenges by combining the natural tumor-killing mechanisms of NK cells with highly selective TCR-based tumor recognition. The company’s approach may potentially improve anti-tumor activity while reducing some of the toxicities associated with earlier generations of engineered cell therapies.
MAGE-A4 has emerged as an increasingly important target in oncology immunotherapy development because of its broad expression across multiple solid cancers, including ovarian cancer, lung cancer, head and neck cancers, sarcomas, and melanoma. Several biotechnology companies are pursuing MAGE-A4-directed therapies; however, Zelluna’s program is differentiated by its use of an allogeneic TCR-NK platform rather than conventional T-cell engineering approaches. Industry observers continue to closely monitor advancements in off-the-shelf cell therapy technologies due to their potential commercial scalability and broader patient access advantages.
Initial Clinical Data Expected to Emerge in Mid-2026
Zelluna stated that with the first site now activated, operational priorities will focus on patient screening, enrollment activities, and progression toward first patient dosing. Chief Executive Officer Namir Hassan described the activation as a critical milestone for the company, signaling the start of active clinical execution for its lead development program. The company has previously guided that initial clinical data from the ZIMA-101 study are expected to emerge beginning in mid-2026, making the program one of the closely watched early-stage solid tumor cell therapy studies in the European biotechnology sector.
Headquartered at the Oslo Cancer Cluster Innovation Park in Norway, Zelluna is positioning itself within the rapidly growing global cell therapy market, where investors and researchers continue seeking next-generation technologies capable of extending immunotherapy success beyond hematologic malignancies into solid tumors. As the competitive landscape evolves, the early clinical performance of ZI-MA4-1 may provide important insight into the viability of TCR-NK-based therapies as a future treatment modality for difficult-to-treat cancers.
Source: Zelluna ASA press release
